Niche drug maker InnoPharma raises $15 million in private equity
This article was originally published in Scrip
Executive Summary
InnoPharma, a Piscataway, New Jersey-based firm that develops sterile injectable and ophthalmic generics and speciality pharmaceuticals for commercial licensing to pharma partners, has raised $15 million in a series A private financing. The funding was led by the healthcare private equity firm Thomas, McNerney & Partners, two partners of which, Alex Zisson and James Thomas, have joined InnoPharma's board of directors.